Back to discover
Disease

Glomerulonephritis, Membranous

Late-stage therapeutic developmentEmerging research
MeSHGlomerulonephritis, Membranous
2
Publications
9
Clinical trials
2
Related proteins
2021
Latest publication
Current focus
Autoantibodies biologyTherapeutic developmentInflammation & immunity
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Membranous nephropathy.

Research2021-09-30Nature reviews. Disease primers

Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.

Research2019-10-07Kidney international

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial with recent milestones (1 completed or reporting results).
Clinical Milestones1View
Results posted 1
Activity timeline1

Clinical trials

8 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
9
All trials
1
Active
7
Late-stage
6
Completed
Late-stage studies

The Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome （PRIME Study）

Phase 3 · Recruiting · Shoichi Maruyama MD PhD

Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG)

Phase 4 · Completed · Imperial College Healthcare NHS Trust

A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy

Phase 3 · Completed · Kyungpook National University Hospital

Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy

Phase 3 · Completed · Radboud University Medical Center

A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)

Phase 3 · Completed · Hospital Authority, Hong Kong

Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study

Phase 2/3 · Completed · Radboud University Medical Center
Recently completed

A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN)

Phase 1/2 · Completed · HI-Bio, A Biogen Company

Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG)

Phase 4 · Completed · Imperial College Healthcare NHS Trust

A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy

Phase 3 · Completed · Kyungpook National University Hospital

Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy

Phase 3 · Completed · Radboud University Medical Center

A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS)

Phase 3 · Completed · Hospital Authority, Hong Kong

Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study

Phase 2/3 · Completed · Radboud University Medical Center

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20202021
Most influential

Membranous nephropathy.

Nature reviews. Disease primers · 2021 · 333 cites

Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.

Kidney international · 2020 · 250 cites
Recent publications

Membranous nephropathy.

Nature reviews. Disease primers · 2021 · 333 cites

Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.

Kidney international · 2020 · 250 cites
Major themes1
  • Glomerulonephritis, Membranous1
Leading journals2
  • Kidney international1
  • Nature reviews. Disease primers1
Leading researchers8
  • Debiec H2
  • Fervenza FC2
  • Ronco P2
  • Sethi S2
  • Beck L1
  • Buob D1
  • Charlesworth MC1
  • Gross L1
Affiliations (unnormalised)6
  • Department of Laboratory Medicine and Pathology2
  • Mayo Clinic2
  • Sorbonne Université2
  • Boston Medical Center and Boston University School of Medicine1
  • Centre for Kidney Research1
  • Centre Hospitalier du Mans1

Disease biology

2 matches

Key proteins & gene products studied in this disease. Number shows shared papers.

Autoantibodies2Receptors, Phospholipase A22

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A type of glomerulonephritis that is characterized by the accumulation of immune deposits (COMPLEMENT MEMBRANE ATTACK COMPLEX) on the outer aspect of the GLOMERULAR BASEMENT MEMBRANE. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.

Identifiers
MeSHGlomerulonephritis, Membranous
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.